ORIC PHARMACEUTICALS INC. - COMMON STOCK

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

15 Apr 2024 16:15:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

08 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

04 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

11 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

06 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

05 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

14 Feb 2024 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2024 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

31 Jan 2024 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

22 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

08 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 16:30:00 By Nasdaq GlobeNewswire

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

11 Dec 2023 12:00:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 Dec 2023 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

09 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

06 Nov 2023 16:10:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

02 Nov 2023 09:00:00 By Nasdaq GlobeNewswire